CAS: 120210-48-2; (Z)-5-Chloro-3-(Hydroxy(Thiophen-2-yl)Methylene)-2-Oxoindoline-1-Carboxamide

该化合物是一种化学化合物,属于非类类类非类类抗炎药物(NSAIDs),主要被确认为具有潜在的抗炎和止炎特性,因此与治疗关节炎等病症有关.通过抑制炎症过程中的特定酶,从而减少疼痛和膨胀,作用复合.Tenidap的特点是其独特的分子结构,包括有助于其生物活动的功能组.它通常以口头形式进行,并研究其药用植物基因学,包括吸收,分布,代谢和排泄.尽管它在临床环境中表现出希望,但Tenidap的使用可能与非典的副作用有关,如胃肠不适或心血管风险.和任何制药剂一样,其治疗用途应当由保健专业人员指导,考虑到病人的具体健康状况和潜在的药物相互作用.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号255712-72-2 (Z)-5-chloro-3-... | CAS号5271-67-0 2-噻吩甲酰氯 | CAS号197776-00-4 N,O-di(phenoxyc... | CAS号255712-71-1 (Z)-5-chloro-3-... | CAS号255712-65-3 5-chloro-1-phen... | CAS号17630-75-0 5-氯氧化吲哚

合成工艺路线路线简述

  • 合成目标产物 Tenidap 主要起始原料 1H-Indole-1-Carboxylic Acid, 5-Chloro-2,3-Dihydro-3-(Hydroxy-2-Thienylmethylene)-2-Oxo-, Phenyl Ester, (3Z)-
  • (文献来源)合成步骤主要原料 1H-Indole-1-Carboxylic Acid, 5-Chloro-2,3-Dihydro-3-(Hydroxy-2-Thienylmethylene)-2-Oxo-, Phenyl Ester, (3Z)-
📜2-噻吩甲酰氯置于盐酸,Ammonium Carbonate体系中,用 二氯甲烷,水,N,N-二甲基甲酰胺 用作溶剂,化学反应 14.0H,反应生成替尼达普
参考文献:替尼达实用新合成
标题:替尼达实用新合成
摘要:描述了一种新的实用合成替尼达普的开发.5-氯-2-氧代-2,3-二氢吲哚的n,O-二烷氧基(芳氧基)羰基化,然后除去o-烷氧基(芳氧基)羰基得到1-[烷氧基(芳氧基)羰基]-5-氯-2-氧代-2,3-二氢吲哚的收率非常好.后一种化合物在 3 位进行了酚化.讨论了 Dmap 在酰化反应中的作用.在溶液和固相中研究了 Thenoylated 产物及其烯醇盐的结构.5-Chloro-3-[1-Hydroxy-1-(2-Thienyl)Methylene]-2-Oxo-1-Phenoxycarbonyl-2,3-Dihydroindole 的氨解以高产率提供相应的 1-Carbamoyl 衍生物 (Tenidap).相应的 1-乙氧基和 1-甲氧基羰基衍生物不能类似地转化为替尼达;
Doi:10.1021/op990067A

海关参考信息

专利信息


专利号:US-8546532-B2
优先权日:2008-04-17
标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

专利号:US-2002183366-A1
优先权日:2001-03-23
标题:Cyclooxygenase-2 inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; SCHROEDER JOSEPH D
摘要:This invention describes novel compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity or other toxicities; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

专利号:US-7211598-B2
优先权日:2002-06-28
标 题:Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; RANATUNGE RAMANI R; RICHARDSON STEWART K
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor having at least one oxime group or hydrazone group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

专利号:US-7244753-B2
优先权日:2002-07-29
标 题:Cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; KHANAPURE SUBHASH P; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

专利号:US-7332505-B2
优先权日:1999-02-26
标 题 :Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; LETTS L GORDON; RICHARDSON STEWART K; TAM SANG WILLIAM; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Thangaraju P, Balan AK, Velmurugan H, Venkatesan S, Yella SST. Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications. Infect Disord Drug Targets. 2023;23(2):e070922208607. doi: 10.2174/1871526522666220907125114. 11(4):482-492. doi: 10.4103/idoj.IDOJ_561_19.
3: Sreedharan R, Rajeshwaran P, Panyam PKR, Yadav S, Nagaraja CM, Gandhi T. Acylation of oxindoles using methyl/phenyl esters via the mixed Claisen condensation - an access to 3-alkylideneoxindoles. Org Biomol Chem. 2020 May 27;18(20):3843-3847. doi: 10.1039/d0ob00789g. 18(8):621-630. doi: 10.2174/1871527318666190807122623.
156:106167. doi: 10.1016/j.eplepsyres.2019.106167. Epub 2019 Jul 15. 32(1):217-220. 38(5):1984-98. doi: 10.1159/000445559. Epub 2016 May 9.

合成参考文献


参考文献:10.1107/s1600536810042522
摘要:Wei WB, Tian S, Zhou H, Sun J, Wang HB. 5-Chloro-indoline-2,3-dione. Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 31;66(Pt 11):o3024.
参考文献:10.1021/jm00093a020
摘要:Suzuki F, Kuroda T, Tamura T, Sato S, Ohmori K, Ichikawa S. New antiinflammatory agents. 2. 5-Phenyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones: a new class of nonsteroidal antiinflammatory agents with potent activity like glucocorticoids. J Med Chem. 1992 Jul 24;35(15):2863–70. doi: 10.1021/jm00093a020.
摘要:Fouda HG, Avery MJ, Dalvie D, Falkner FC, Melvin LS, Ronfeld RA. Disposition and metabolism of tenidap in the rat. Drug Metab Dispos. 1997 Feb;25(2):140–8.
参考文献:10.1189/jlb.0807553
摘要:Bréchard S, Tschirhart EJ. Regulation of superoxide production in neutrophils: role of calcium influx. J Leukoc Biol. 2008 Nov;84(5):1223–37.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知